US-based Thermo Fisher Scientific will use their new Inchinnan facility, near Glasgow, to manufacture products needed for the production of biotherapeutics and vaccines for diseases such as cancer, influenza and Dengue fever.
This investment is linked to on-going support from Scottish Development International to assist the company in expanding its global manufacturing network.
A total of 30 new jobs have been created at the plant, where Thermo Scientific already employs around 600 staff.
“This is a strategically important facility that will secure supplies for our target markets all over the world,” said Mark Smedley, President of Europe, Middle East and Africa, Life Sciences Solutions, for Thermo Fisher (above, left). “It’s important to choose the right location for a factory of this significance, and we felt the depth of experience, skills and expertise at Inchinnan made it the perfect place to make this investment.”
We felt the depth of experience, skills and expertise at Inchinnan made it the perfect place to make this investment.
Mark Smedley, President and EMEA General Manager, Life Sciences, Thermo Fisher
Expansion confirms Scotland's multiple attractions
Paul Lewis, Managing Director, Scottish Enterprise International Operations, said:
"Scotland is already home to a thriving life sciences cluster which is recognised worldwide as one of the most accessible, well-connected and collaborative in Europe. It is major investments like this that allow us to continue to attract ambitious, international companies such as Thermo Fisher to not only locate in Scotland, but to strengthen their business.”
Leading the fight
The company, which operates in 50 countries and employs more than 50,000 people, is developing leading edge technologies to enable the global fight against cancer and contagious diseases.
The expanded Renfrewshire plant will manufacture a proprietary dry media powder known as Gibco™ Advanced Granulation Technology (AGT); an animal-origin free, single-component, particulate-free powder for chemically defined cell culture. The product is used for biological drug research, development and production.
The dry format reduces the number of components necessary in cell culture manufacturing processes. Used to manufacture biologics, including vaccines, anti-cancer therapeutics and other life-saving drugs, AGT offers the benefits of traditional liquid media without the associated cost, storage, and transportation challenges.
The £14m investment increases the assurance of supply for customers and complements another Thermo Fisher plant in Grand Island, New York, where AGT is also manufactured. The new facility will add to the Inchinnan site’s existing manufacturing operations, which produce liquid media for a range of research and production applications.
Location, location, location…
Scotland is home to 600 life sciences organisations, employing 30,000 people.
Our company base includes around:
- 250 medical technology companies (with another 100 involved in their value chain)
- 160 pharma services companies
- 5 of the world's top 10 CROs (PPD, Bioreliance, Charles River, Quintiles, Catalent)
- Over 30 companies working on stem cells and regenerative medicine
Thanks to our compact geography, Scotland is highly inter-connected with both Europe and the wider world and our outstanding logistics, cold chain and packaging capability enables the time-critical shipment of cells and biological products into and out of the country.
Plus we have Health Innovation Partnerships that facilitate collaboration between industry, academia and clinicians to develop products for future healthcare needs.
The quality of Scotland's research and development and skilled workforce are key reasons why companies such as Thermo Fisher Scientific choose to locate here. Link that to the support available from both Scottish Enterprise and ourselves and you have a recipe for success.
Ready to work with Scotland's Life Sciences sector or want to know more?
Contact us now